{"title": "Johnson & Johnson unloads eye drops line to acquisitive Bausch + Lomb as Brent Saunders' deal streak rolls on", "author": "Angus Liu", "url": "https://www.fiercepharma.com/pharma/jj-unloads-eye-drops-line-bausch-lomb-brent-saunders-tackles-underutilization-ma", "hostname": "fiercepharma.com", "description": "During the first earnings call Brent Saunders led since his return at Bausch + Lomb, the CEO laid out what he believes is the company's biggest issue: underutilization of existing infrastructure. | During the first earnings call Brent Saunders led since his return at Bausch + Lomb, the CEO laid out what he believes is the company's biggest issue: underutilization of existing infrastructure. Now, he is tackling the problem through M&A.", "sitename": "FiercePharma", "date": "2023-07-06", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}